Title: The Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-
Related Advanced Fibrosis and Cirrhosis in the United States Population Utilizing AGILE 3+
and AGILE 4 Scores: Analysis of the NHANES 2017-2018 Cycle
Version: 1 Date: 26 May 2024
Reviewer's report:
The authors have made significant clarifications.
Few additional comments:
1. Since the nomenclature was changed from NAFLD to MASLD upon recommendations of
the editors, the authors did so but the definition of MASLD being a CAP >248 alone would
not be MASLD as MASLD requires hepatic steatosis plus one or more cardiometabolic risk
factors. Hepatic steatosis without cardiometabolic risk factor would be cryptogenic SLD. Can the
authors clarify if the change from NAFLD to MASLD affected their sample size and subsequent
analysis?
2. Must have been missed during the initial review, should it not be AGILE 4 and not AGILE
4+?  https://pubmed.ncbi.nlm.nih.gov/36375686/
Title: The Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-
Related Advanced Fibrosis and Cirrhosis in the United States Population Utilizing AGILE 3+
and AGILE 4 Scores: Analysis of the NHANES 2017-2018 Cycle
Version: 1 Date: 26 May 2024
Reviewer's report:
The authors have made significant clarifications.
Few additional comments:
1. Since the nomenclature was changed from NAFLD to MASLD upon recommendations of
the editors, the authors did so but the definition of MASLD being a CAP >248 alone would
not be MASLD as MASLD requires hepatic steatosis plus one or more cardiometabolic risk
factors. Hepatic steatosis without cardiometabolic risk factor would be cryptogenic SLD. Can the
authors clarify if the change from NAFLD to MASLD affected their sample size and subsequent
analysis?
2. Must have been missed during the initial review, should it not be AGILE 4 and not AGILE
4+?  https://pubmed.ncbi.nlm.nih.gov/36375686/
Please review this paper.
user
Title: The Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-
Related Advanced Fibrosis and Cirrhosis in the United States Population Utilizing AGILE 3+
and AGILE 4 Scores: Analysis of the NHANES 2017-2018 Cycle
Version: 1 Date: 26 May 2024
Reviewer's report:
The authors have made significant clarifications.
Few additional comments:
1. Since the nomenclature was changed from NAFLD to MASLD upon recommendations of
the editors, the authors did so but the definition of MASLD being a CAP >248 alone would
not be MASLD as MASLD requires hepatic steatosis plus one or more cardiometabolic risk
factors. Hepatic steatosis without cardiometabolic risk factor would be cryptogenic SLD. Can the
authors clarify if the change from NAFLD to MASLD affected their sample size and subsequent
analysis?
2. Must have been missed during the initial review, should it not be AGILE 4 and not AGILE
4+?  https://pubmed.ncbi.nlm.nih.gov/36375686/
assistant